Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Santhera and NIH collaborate to evaluate Catena® in primary progressive multiple sclerosis
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.
Interferon beta-1b-induced Sweet's syndrome in a patient with multiple sclerosis.
Myelin in cartilaginous fish.
Imovane: Best Online Pharmacy
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.
Launch of a phase 3 clinical trial in the treatment of Alzheimer’s disease with masitinib
Immune competence after alemtuzumab treatment of multiple sclerosis.
An Exploratory Investigation of Social Stigma and Concealment in Patients with Multiple Sclerosis.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Teriflunomide for multiple sclerosis.
Dimethylfumarate protects against TNF-α-induced secretion of inflammatory cytokines in human endothelial cells.
Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Multiple sclerosis and neuromyelitis optica spectrum disorders: some similarities in two distinct diseases.
UCSF Seminar: "Antibody Repertoire Sequencing"
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder.

Pages